Canakinumab – March 2026

Solution for injection 150 mg in 1 mL,

  • Brand names:
    • Ilaris®
  • Pharmaceutical Company:
    • NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED
  • Condition/Indication: Colchicine-resistant or intolerant Familial Mediterranean Fever (crFMF)
  • Meeting Date: March 2026
Public Summary Documents
Last updated
11 March 2026